The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.
 
Eric Thompson
Consulting or Advisory Role - Oncoheroes Biosciences
Patents, Royalties, Other Intellectual Property - Duke University
 
David M. Ashley
No Relationships to Disclose
 
Kathy Ayasoufi
No Relationships to Disclose
 
Pamela Norberg
No Relationships to Disclose
 
Gerald E. Archer
No Relationships to Disclose
 
Evan Buckley
No Relationships to Disclose
 
JAMES E HERNDON
No Relationships to Disclose
 
Ashley Walter
Employment - Day One Biopharmaceuticals; Gentech (I)
Stock and Other Ownership Interests - Day One Biopharmaceuticals (I); Gentech (I)
 
Bridget Archambault
No Relationships to Disclose
 
Charlene Flahiff
Employment - AUNC
Travel, Accommodations, Expenses - Proverum Medical; Zenflow
 
Denise Jaggers
No Relationships to Disclose
 
Laura Gorski
No Relationships to Disclose
 
Elizabeth A. Reap
Employment - Q2 Solutions- Genomics Lab, Genomic Services
 
Kristin Schroeder
No Relationships to Disclose
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Biodexa; Orbus Therapeutics
Research Funding - Biodexa (Inst); Orbus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - AU 2019247039 NEOADJUVANT CANCER TREATMENT; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; Canada NEOADJUVANT CANCER TREATMENT; China NEOADJUVANT CANCER TREATMENT; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2020-554198 NEOADJUVANT CANCER TREATMENT; PCT/US2019/025402 NEOADJUVANT CANCER TREATMENT; South Korea 10-2020-7031272 NEOADJUVANT CANCER TREATMENT; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; US 16/086,735 SEQUENTIAL ANTI-CANCER TREATMENT; US 16/505,771 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/016,699 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/044,645 NEOADJUVANT CANCER TREATMENT; US 62/651,470; US 62/823,277 NEOADJUVANT CANCER TREATMENT
 
Margaret O Johnson
No Relationships to Disclose
 
Katherine B. Peters
Consulting or Advisory Role - Anheart Therapeutics; Blue Earth Diagnostics; NuvOx Pharma; Ono Pharmaceutical; Rigel; Sapience Therapeutics; SERVIER; Telix Pharmaceuticals
Research Funding - Abbvie; BioMimetix; Novocure; Sapience Therapeutics; SERVIER; Varian Medical Systems
Other Relationship - Eisai Europe
(OPTIONAL) Uncompensated Relationships - Vivacitas Oncology
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; George Clincal; Janssen; Lilly; Novocure; Roche; SERVIER; Stemline Therapeutics; Voyager Therapeutics
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); cns pharmaceuticals (Inst); daiichi Sankyo (Inst); Immorna (Inst); Immvira (Inst); Personalis (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
John H. Sampson
Leadership - Annias Immunotherapeutics; Medicenna
Stock and Other Ownership Interests - Annias Immunotherapeutics; Immunomic Therapeutics; Insera Health; ISTARI Oncology; Neuronium
Research Funding - Annias Immunotherapeutics; ISTARI Oncology
Patents, Royalties, Other Intellectual Property - Annias Immunotherapeutics; ISTARI Oncology; Neuronium
Other Relationship - Annias Immunotherapeutics; Celldex
 
Daniel B Landi
No Relationships to Disclose